In a patient with pancreatic cancer who is heterozygous for the ATM c.875C>T (Pro292Leu) mutation with functional impairment in the gene product, is there any data or recommendation to support using SBRT vs. chemo-RT?

Ablative-dose radiation (100 Gy BED) is a curative option, with LC and OS similar to surgery. Everything else is palliative. 50 Gy in 5 fx with MRgRT is an evolving standard. The patient should be informed that this option is available at many centers. Otherwise, any palliative dose is fine.

With th...